F9 gene therapy (SR-TIGET/Bioverativ)

N/A

Report date: 2025/01/26 17:09:10

Base Information

Drug NameF9 gene therapy (SR-TIGET/Bioverativ)
Drug Alias NameFactor IX gene therapy (San Raffaele Telethon Institute/MolMed)CD47hi-LVlentiviral gene therapy (San Raffaele Telethon Institute/Biogen)lentiviral gene therapy (San Raffaele Telethon Institute/Biogen Idec)
ClassificationBiologics
Mechanisms of ActionCoagulation factor IX stimulants
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe San Raffaele Telethon Institute For Gene Therapy
China Registration ClassN/A

Develop Information

Active CompaniesThe San Raffaele Telethon Institute For Gene TherapyBioverativ Inc
Inactive CompaniesAgc BiologicsBiogen Inc
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A